Pharma Contract Sales Industry and Market: Trends and Forecasts 2015-2025

医薬品販売業務受託機関(CSO)の世界市場

◆タイトル:Pharma Contract Sales Industry and Market: Trends and Forecasts 2015-2025
◆商品コード:VGAIN503176
◆調査・発行会社:visiongain
◆発行日:2015年3月
◆ページ数:216
◆レポート形式:PDF / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single UserGBP1,799 ⇒換算¥269,850見積依頼/購入/質問フォーム
Five UserGBP2,999 ⇒換算¥449,850見積依頼/購入/質問フォーム
Site License(全社内共有可)GBP4,999 ⇒換算¥749,850見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

当調査レポートでは、医薬品販売業務受託機関(CSO)の世界市場について調査・分析し、以下の構成でお届けいたします。

・レポートの概要
・イントロダクション
・医薬品販売業務受託の世界市場
 (市場規模予測、市場の成長要因・阻害要因など)
・主要なサービス分野
・セグメント別市場分析
・地域別市場分析
・市場環境分析
・専門家の見解
・主要な医薬品販売業務受託機関(CSO)分析
・結論

Outsourced selling of medicines – how to find trends, opportunities and potential revenues
What’s the future of outsourcing pharma sales activities? For prescription drugs, get new forecasts for contracted promotional activities. Stay ahead, then, for data. There you explore business results, progress, trends, strategies and predicted revenues.

Visiongain’s updated report shows what’s possible for those pharmaceutical services. Avoid missing out on opportunities. Instead explore advances in medical detailing and potential gains for contract sales organisations (CSOs).

Please read on, then, to investigate that expanding healthcare industry, seeing what its future could be worth. For that outsourcing you assess expected developments.

Forecasts and other information showing opportunity in pharmaceutical sales contracting
Progress worldwide in healthcare expands use of out-contracted services for promoting and selling human medicines. There see what’s possible.

Besides forecasting revenues to 2025, the new analysis shows historical data, recent results, growth rates and market shares. There you gain feel for companies’ outlooks and potentials. You also get 77 tables, 64 charts and three interviews with that industry.

Knowledge to help your work and save time, benefiting your influence
Our study shows you revenue predictions to 2025 at overall world, submarket and national level. For those service offerings you investigate where money lies. Find what’s happening.

And avoid struggles to find business information on outsourced drug selling. Our report helps your research, analyses and decisions for medical sales. Save time, too, and stay ahead.

Also – by gaining in knowledge of the present and future – benefit your authority through increased technological and commercial insight.

And the following sections highlight, in detail, what the new investigation gives you.

Forecasting of that world market and its segments – what’s likely to happen?
What’re the secrets of that industry’s progress? And what’s its potential? Discover in our report overall world revenue to 2025 for contract pharma sales operations.

Also see individual predictions of revenues to 2025 for 11 submarkets at world level:
• Field sales (detailing)
• Non-personal promotion, also with sub-forecasting for teledetailing, e-detailing and other selling functions
• Medical education
• Sample management activities
• Other outsourced promotional services.

And get forecasts by therapeutic application:
• Cardiovascular disease therapies
• Metabolic disorder treatments
• Cancer-treating agents.

There you assess prospects for outsourced medicine sales, hearing where you can gain. Investigate competition and increasing revenues. So discover lucrative possibilities for syndicated pharma sales teams and related promotional activities.

Our investigation also shows you geographical predictions for CSOs and their teams.

Healthcare in national markets – commercial outlooks for medical sales contracting
That study shows countries having great potential for those outsourced and off-shored selling operations. See where and how you could profit, assessing predicted revenues.

Our analyses show you individual revenue forecasts to 2025 for 11 national markets:
• United States (US)
• Japan
• Germany, France, UK, Italy and Spain (EU5), also with EU regional prediction
• Brazil, Russia, India and China (BRIC nations).

There you find regions and countries with highest revenues, demands and potential sales growth. Stay ahead, then, for information, finding international prospects for that promoting and selling to doctors and other medical practitioners.

And what events change that market? Our work shows you, discussing trends and needs.

Developments, challenges and events influencing contract sales organisations
The report also explains issues affecting the CSO industry and market from 2015:
• Outsourced and in-house sales reps – trends and emerging sales models, including multiple channels (multichannel marketing to medical professionals)
• Services CSOs offer and benefits to drug companies outsourcing medical sales
• Maturing brands and product launches, including flexibility in field sales teams
• Legislation and new market access requirements for pharma sales representatives – regulatory outlooks
• Changes to online marketing and potential for recent and emerging IT technologies
• Risk-sharing agreements, key account management (KAM), key opinion leaders (KOLs) and medical science liaison (MSL).

And you explore these influences, too, among others:
• Smartphones and tablets for detailing – advances in communication technology
• Closed loop marketing (CLM), cloud computing and customer relationship management (CRM), including social media and big data
• Changes to in-house sales staffing levels – rising demand for outsourcing service providers
• Demand for inside and outside medical sales teams, as well as increasing needs for contact centres
• Strategic partnering and CSO consolidation – links, networks and alliances
• Promotion of biologics, biosimilars, orphan drugs and other specialty medicines.

There investigate what stimulates and restrains competitors in that industry, and affects its results. You also get SWOT and STEP analyses.

Companies and potential for sales increases – what gains are possible?
That study predicts the world market for pharma contract selling will rise to $6.46bn in 2019, with strong revenue expansion from 2015 to 2025. Those services have increasing demand.

There large pharma service contractors and specialists can prosper, expanding business. Our new analysis shows you gains possible.

So what happens next? In particular, that report assesses these companies’ activities:
• Quintiles
• inVentiv Health
• UDG Healthcare
• Publicis Touchpoint Solutions
• OnCall
• PDI.

【レポートの目次】

1. Report Overview
1.1 Pharma Contract Sales: World Market Review 2014
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by this Analysis
1.5 Who Is This Study For?
1.6 Methods of Research and Analysis
1.7 Frequently Asked Questions (FAQs)
1.8 Some Associated Reports
1.9 About Visiongain

2. Defining the Pharma Contract Sales Market
2.1 An Introduction to Pharma Contract Sales
2.2 Pharma Sales Models 2014 – Multiple Channels
2.3 Detailing Healthcare Professionals – Is That Still Relevant?
2.4 There Are Benefits to Outsourcing Pharma Sales
2.4.1 What Services Do CSOs Offer?
2.4.2 The Rise in Pharma Contract Sales
2.5 The Need for New Sales Models – Creative Yet Ethical

3. World Pharma Contract Sales Market: Outlook and Forecast 2015-2025
3.1 World Pharma Contract Sales Market 2014
3.1.1 Pharma Contract Sales Market by Sector 2014
3.1.2 Recent Growth in Outsourced Pharma Sales
3.2 World Pharma Contract Sales Market Forecast 2015-2025
3.2.1 Maturing Brands and New Product Launches to Drive Growth to 2025
3.2.2 Increasing Restraints on Healthcare Budgets to Drive Market Access Consultancy
3.2.3 Pharma Contract Sales: Market Restraints 2015-2025
3.3 Leading Therapeutic Areas for Pharma Contract Sales 2015-2025
3.4 Contract Sales for Cardiovascular Drugs 2015-2025
3.4.1 Growth for Cardiovascular Disease Services: Submarket Forecast 2015-2025
3.5 Metabolic Disorders: Pharma Contract Sales 2015-2025
3.5.1 Metabolic Disorder Services: New Obesity and Diabetes Product Launches Drive to Growth 2015-2025
3.6 Contract Sales for Cancer Drugs 2015-2025
3.6.1 Oncology Sales Services: Submarket Forecast 2015-2025
3.7 Chapter Summary: Strong Growth Forecast for the Pharma Contract Sales Market 2015-2025

4. Leading Service Sectors of the Pharma Contract Sales Market 2015-2025
4.1 Detailing Leads the Contract Sales Market 2014
4.1.1 Rising Demand for Inside and Outside Sales Teams
4.2 Personal Promotion: Contract Detailing Submarket 2015-2025
4.2.1 Detailing Services Offered by CSOs
4.2.2 Contract Detailing: Submarket Forecast 2015-2025
4.2.3 CSOs Are Affected by Doctor Access as Much as Internal Reps
4.2.4 Field Sales Flexibility to Drive Submarket Growth 2015-2025
4.3 Contract Non-Personal Promotion Submarket 2015-2025
4.3.1 Contract Non-Personal Promotion: Submarket Forecast 2015-2025
4.3.1.1 Submarket Drivers and Restraints 2015-2025: Multichannel Marketing
4.3.2 Contract Teledetailing Submarket 2015-2025
4.3.2.1 Submarket Forecast 2015-2025: Rapid Growth in Demand for Contact Centres
4.3.2.2 Contract Teledetailing: Submarket Drivers and Restraints 2015-2025
4.3.3 Contract eDetailing Submarket 2015-2025
4.3.3.1 The Contract Edetailing Submarket Will Grow Fastest 2015-2025
4.3.3.2 Contract Edetailing: Submarket Drivers and Restraints 2015-2025
4.4 Medical Education Services Submarket 2015-2025
4.4.1 Medical Education Services Submarket: Revenue Forecast 2015-2025
4.4.2 Complex Drug Development to Drive Submarket Growth to 2025
4.5 Sample Management Services Submarket 2015-2025
4.5.1 Steady Growth for Sample Management Services to 2025
4.5.2 Sample Management Services: Submarket Drivers and Restraints 2015-2025
4.5.3 J. Knipper & Co.: A US Leader in Sample Management Services
4.5.3.1 J. Knipper Acquires Sample Management Divisions from Leading CSOs 2010-2014
4.5.3.2 New Technologies to Drive Growth 2015-2025
4.6 Chapter Summary: Continued High Demand for Contract Detailing Services

5. Leading National Submarkets for Pharma Contract Sales: Regulatory and Commercial Outlook 2015-2025
5.1 Leading National Submarkets for Pharma Contract Sales 2014
5.2 Leading National Pharma Contract Sales Submarkets: Outlook and Forecast 2015-2025
5.2.1 How Will Market Shares for Leading Countries Change to 2025?
5.3 Pharma Sales Regulatory Developments
5.3.1 Physician Payment Legislation in the US, Europe and Japan 2011-2014
5.3.1.1 The Physician Payment Sunshine Act (PPSA)
5.3.1.2 Physician Payments in France: Increased Scrutiny from 2013
5.3.2 Domestic and International Concerns over Bribery: Recent Legislation in the US and UK
5.3.2.1 Promotional Products in the EU: New Rules 2013
5.3.3 New Market Access Requirements in EU5 Countries 2011-2014
5.3.3.1 AMNOG: Stricter Pricing for Drugs in Germany
5.3.3.2 Healthcare Reform in France: Pricing and Reimbursement Set for Change?
5.3.3.3 Pricing Models and Clinical Commissioning Groups in the UK
5.3.4 Overtime for Sales Reps in the US: Rule Clarifications 2012-2014
5.4 The US Pharma Contract Sales Submarket 2015-2025
5.4.1 Pharma Sales Regulation in the US
5.4.2 US Submarket: Revenue Forecast 2015-2025
5.5 Pharma Contract Sales in the EU 2015-2025
5.5.1 Regulating Pharma Sales in the EU
5.5.2 Commercial Outlook for Pharma Contract Sales in the EU: Submarket Forecast 2015-2025
5.5.3 UK Submarket: Revenue Forecast 2015-2025
5.5.4 Strong Growth for the German Submarket to 2025
5.5.5 French Pharma Contract Sales Submarket: Revenue Forecast 2015-2025
5.5.6 Italian Submarket Forecast 2015-2025: Price Restrictions to Restrain Growth
5.5.7 Spanish Pharma Contract Sales Submarket: Revenue Forecast 2015-2025
5.6 Japanese Pharma Contract Sales: Regulatory and Commercial Outlook 2015-2025
5.6.1 Pharma Contract Sales in Japan 2013-2014
5.6.2 Rise in Outsourcing Rate to Drive Japanese Submarket Growth 2015-2025
5.7 Chapter Summary: Strong Growth for Leading National Submarkets 2015-2025

6. Emerging National Submarkets for Pharma Contract Sales: Regulatory and Commercial Outlook 2015-2025
6.1 Pharma Contract Sales in Emerging National Submarkets 2014
6.2 Outlook for Emerging National Submarkets: Revenue Forecasts 2015-2025
6.3 Improving Regulation for Pharma Sales in Emerging Markets
6.4 Pharma Contract Sales in China 2015-2025
6.4.1 Rising In-House and Outsourced Sales Rep Numbers 2011-2013
6.4.2 Concerns over Bribery in Chinese Pharma Sales
6.4.3 Chinese Pharma Contract Sales Submarket: Revenue Forecast 2015-2025
6.5 India: Pharma Contract Sales Submarket 2015-2025
6.5.1 New Pharma Sales Rules Proposed for 2015
6.5.2 Demand for Field Sales Teams to Drive Growth in the Indian Submarket Growth to 2025
6.6 Pharma Contract Sales in Brazil 2015-2025
6.6.1 State Payment Rules for Drugs in Brazil
6.6.2 Updated Online Marketing Rules for Prescription Drugs
6.6.3 Brazilian Pharma Contract Sales Submarket: Revenue Forecast 2015-2025
6.7 Pharma Contract Sales in Russia 2015-2025
6.7.1 New State Procurement Rules for Drugs 2013
6.7.2 Restricted Interactions between Doctors and Sales Reps in Russia
6.7.3 Russian Pharma Contract Sales Submarket: Revenue Forecast 2015-2025
6.8 Chapter Summary: Outlook for Pharma Contract Sales in Emerging National Markets 2015-2025

7. Pharma Contract Sales: Industry and Market Trends 2015-2025
7.1 Pharma Contract Sales Market: Strengths and Weaknesses 2015
7.2 Pharma Contract Sales Market: Opportunities and Threats 2015-2025
7.3 Pharma Contract Sales Market: STEP Analysis 2015-2025
7.3.1 Social Factors Affecting Pharma Sales to 2025
7.3.1.1 The Role of Ethics in Pharma Sales
7.3.2 Technological Developments to Improve Sales Strategies
7.3.2.1 Smartphones and Tablets for New Detailing Strategies
7.3.2.2 Closed Loop Marketing (CLM)
7.3.2.3 Cloud Computing and its Use Pharma Contract Sales
7.3.2.4 Customer Relationship Management (CRM)
7.3.2.5 Can Big Data Play a Role in Pharma Sales?
7.3.2.6 How Will Pharma Use Social Media in Sales?
7.3.3 Economic Pressures Are Limiting Healthcare and Marketing Budgets
7.3.4 Political Issues: Stricter Regulations for Pharma Sales in Markets Worldwide
7.4 Trends in Outsourced Pharma Sales 2015-2025
7.4.1 Cuts to In-House Sales Staff Will Continue from 2015
7.4.2 Strategic Partnering to Provide Long-Term Revenue Growth
7.4.3 Leading CSOs Will Consolidate to Increase Market Penetration
7.4.4 There Are Risks in Outsourcing Pharma Sales
7.5 Drug Development Trends Affecting Pharma Sales 2015-2025
7.5.1 How Will Orphan Drug Development Influence Pharma Sales?
7.5.2 Promotion for Biosimilars Drugs 2015-2025
7.5.3 There Will be Greater Demand for Specialty Medicine
7.5.4 The Appeal of Emerging National Markets
7.6 New Sales Models Are Needed
7.6.1 Sales Reps Are Struggling for Access to Healthcare Professionals
7.6.2 Multichannel Marketing to Overcome Problems of Access
7.6.3 Key Account Management (KAM)
7.6.4 Silos in Sales and Marketing
7.6.5 The Use of Key Opinion Leaders (KOLs) in Pharma Sales
7.7 Market Access and Contract Medicine Sales
7.7.1 There Are Emerging Stakeholders in Pharma Sales
7.7.2 Changes in Market Access in the US 2015-2025: The Rise of ACOs
7.7.3 Market Access in the EU 2015-2025
7.7.4 The Role of CSOs in Improved Market Access
7.8 Chapter Summary: Main Trends Shaping Pharma Contract Sales 2015-2025

8. Leading Contract Sales Organisations (CSOs), 2015
8.1 Few CSOs Compete on a Global Scale
8.2 Quintiles: World Market Leader for Contract Sales and Market Access
8.2.1 New Services and Strategic Partnerships
8.2.2 Quintiles Integrated Healthcare Services: Performance 2010-2014
8.2.3 Outlook for Quintiles’ Contract Sales 2015-2025
8.3 inVentiv Health
8.3.1 inVentiv is Expanding in Asia
8.3.2 inVentiv’s Commercial Services: Recent Financial Performance
8.3.3 inVentiv Health: Contract Sales Outlook 2015-2025
8.4 UDG Healthcare
8.4.1 Geographic and Service Growth through Acquisitions
8.4.2 UDG Healthcare: Financial Performance 2010-2014
8.4.3 A Leader in Europe 2015-2025?
8.5 North America: Leading Regional-Level CSOs
8.5.1 PDI
8.5.1.1 Broad Service Portfolio
8.5.1.2 New Sales Models for Medical Devices
8.5.1.3 Financial Performance 2010-2014
8.5.1.4 PDI: Contract Sales Outlook 2015-2025
8.5.2 Publicis Touchpoint Solutions
8.5.2.1 New Services in Recent Years
8.5.3 OnCall
8.5.3.1 OnCall Partners with Promius Pharma
8.6 Leading Domestic CSOs in Europe
8.6.1 Marvecs: A Local Leader in Germany
8.6.1.1 New Services Added: Sales 3.0
8.6.2 Sofip: Contract Sales for the French Submarket
8.7 CSOs in the Asia Pacific Region
8.7.1 Global Leaders Dominate in Japan
8.7.2 CMIC Accounts for 10% of Outsourced Sales Reps in Japan
8.7.2.1 CMIC CSO: Financial Performance 2010-2014
8.7.3 Leading Players in China Are Not Just CSOs
8.8 Chapter Summary: Growth Strategies for Market Leaders

9. Interviews from Visiongain’s Industry Survey
9.1 Walter R. Dewees, Executive Vice-President, OnCall LLC
9.1.1 OnCall, LLC
9.1.2 Promotional Outsourcing in the US
9.1.3 Increasing Engagement via Technology-Enabled Multi-Channels
9.1.4 Growing Medical Science Liaison Function
9.1.5 Risk-Sharing Agreement
9.2 Tony Swift, Managing Director, Apodi, UK
9.2.1 Apodi
9.2.2 Market Access Challenges in the UK
9.2.3 CSOs Can Promote Partnership Between Pharma and the NHS
9.2.4 Value Propositions Offered by CSOs
9.3 Holger C.W. Fürstenberg, CEO, Hilver, the Netherlands
9.3.1 Hilver
9.3.2 Integrating CLM and Digital Strategy Remains a Challenge
9.3.3 CLM Implementation – Bridging Sales and Marketing
9.3.4 Company Culture is yet to Fully Embrace Digital Toolsets
9.3.5 Digital Tools Facilitate Unparalleled Customer Service

10. Conclusions of the Research and Analysis
10.1 The World Pharma Contract Sales Market in 2014
10.1.1 Contract Detailing Services Dominate CSO Revenues in 2014
10.1.2 Spending on Contract Sales is Highest in the US and EU
10.2 Outlook for the Pharma Contract Sales Market 2015-2025
10.2.1 Growth Trends for Leading Submarkets 2015-2025
10.2.1.1 Therapeutic Sector Growth 2015-2025
10.2.2 Commercial Drivers for Pharma Contract Sales from 2015

List of Tables
Table 1.1 Sales as a Cost for Big Pharma Companies, 2014
Table 1.2 Pharma Contract Sales Industry and Market: Overall Market and Revenue Forecasts by Sector ($bn), 2015-2025
Table 2.1 Benefits and Weaknesses to Outsourcing Pharma Sales, 2015
Table 2.2 Some Big Pharma Sales Force Cuts, Based on Reports and Predictions
Table 3.1 Leading CSO Revenues and CAGRs (%), 2010 and 2014
Table 3.2 Pharma Contract Sales Market: Revenues ($bn), 2010-2014
Table 3.3 Pharma Contract Sales Market: Overall Market and Revenue Forecasts ($bn) by Promotional Activity, 2015-2025
Table 3.4 Pharma Contract Sales Market: Revenues ($bn) and Market Shares (%) by Therapeutic Sector, 2014
Table 3.5 Pharma Contract Sales Market: Therapeutic Submarket Shares (%), 2014-2025
Table 3.6 Cardiovascular Disease Drugs – Patents Expired in 2014
Table 3.7 Cardiovascular Disease Drugs Going Off-Patent, 2015-2025
Table 3.8 Cardiovascular Disease Submarket: Revenue Forecast ($bn), 2014-2025
Table 3.9 Cardiovascular Disease Drugs Approved, 2014-2015
Table 3.10 Metabolic Disorders Drug Off Patent 2016-2022
Table 3.11 Metabolic Disorders Drugs Approved in 2014-2015
Table 3.12 Metabolic Disorder Submarket: Revenue Forecast ($bn), 2014-2025
Table 3.13 Anti-Cancer Drugs Off-Patent, 2015-2020
Table 3.14 Selected Cancer Drugs Facing Market Access Challenges from NICE, 2013-2015
Table 3.15 Oncology Submarket: Revenue Forecast ($bn), 2014-2025
Table 3.16 Anti-Cancer Drugs Approved in 2014-2015
Table 4.1 Pharma Contract Sales Market: Revenues ($bn) and Market Shares (%) by Service Sector, 2014
Table 4.2 Contract Detailing Submarket: Revenues ($bn), 2010-2014
Table 4.3 Contract Detailing Submarket: Revenue Forecast ($bn), 2014-2025
Table 4.4 Contract Non-Personal Promotion Submarket: Revenues ($bn) and Submarket Shares (%) by Sector, 2014
Table 4.5 Contract Non-Personal Promotion: Overall Submarket and Revenue Forecasts ($bn) by Sector, 2014-2025
Table 4.6 Contract Non-Personal Promotion Submarket: Subsector Shares (%), 2014-2025
Table 4.7 Contract Teledetailing Submarket: Revenue Forecast ($bn), 2014-2025
Table 4.8 Contract Edetailing Submarket: Revenue Forecast ($bn), 2014-2025
Table 4.9 Medical Education Services Submarket: Revenue Forecast ($bn), 2014-2025
Table 4.10 Sample Management Services Submarket: Revenue Forecast ($bn), 2014-2025
Table 4.11 Pharma Contract Sales Market: Overall Market and Revenue Forecasts ($bn) by Service Type, 2014-2025
Table 4.12 Pharma Contract Sales: Market Shares (%) by Service Type, 2014-2025
Table 5.1 Pharma Contract Sales Market: Revenues ($bn) and Market Shares (%) by Leading Country, 2014
Table 5.2 Pharma Contract Sales Market: Overall Market and Revenue Forecasts ($bn) by Region, 2014-2025
Table 5.3 Pharma Contract Sales: Market Shares (%) by Region, 2014-2025
Table 5.4 US Pharma Contract Sales Submarket: Revenues ($bn), 1995 and 2014
Table 5.5 US Pharma Contract Sales Submarket: Revenue Forecast ($bn), 2014-2025
Table 5.6 US Pharma Contract Sales Submarket: Drivers and Restraints, 2015-2025
Table 5.7 EU Pharma Contract Sales Submarket: Revenues ($bn) and Submarket Shares (%) by Leading Country, 2014
Table 5.8 EU Pharma Contract Sales Submarket: Overall Submarket and Revenue Forecasts ($bn) by Leading Country, 2014-2025
Table 5.9 EU Pharma Contract Sales Submarket: Drivers and Restraints, 2015-2025
Table 5.10 UK Pharma Contract Sales Submarket: Revenue Forecast ($bn), 2014-2025
Table 5.11 German Pharma Contract Sales Submarket: Revenue Forecast ($bn), 2014-2025
Table 5.12 French Pharma Contract Sales Submarket: Revenue Forecast ($bn), 2014-2025
Table 5.13 Italian Pharma Contract Sales Submarket: Revenue Forecast ($bn), 2014-2025
Table 5.14 Spanish Pharma Contract Sales Submarket: Revenue Forecast ($bn), 2014-2025
Table 5.15 Japanese Pharma Contract Sales Submarket: Revenue Forecast ($bn), 2014-2025
Table 5.16 Japanese Pharma Contract Sales Submarket: Drivers and Restraints, 2015-2025
Table 6.1 Pharma Contract Sales Market: Revenue Forecasts ($bn) for Four Leading Emerging Countries (BRIC Nations), 2014-2025
Table 6.2 Pharma Contract Sales: Leading Emerging Market Shares (%), 2014-2025
Table 6.3 Chinese Pharma Contract Sales Submarket: Drivers and Restraints, 2015-2025
Table 6.4 Chinese Pharma Contract Sales Submarket: Revenue Forecast ($bn), 2014-2025
Table 6.5 Indian Pharma Contract Sales Submarket: Revenue Forecast ($bn), 2014-2025
Table 6.6 Indian Pharma Contract Sales Submarket: Drivers and Restraints, 2015-2025
Table 6.7 Brazilian Pharma Contract Sales Submarket: Drivers and Restraints, 2015-2025
Table 6.8 Brazilian Pharma Contract Sales Submarket: Revenue Forecast ($bn), 2014-2025
Table 6.9 Russian Pharma Contract Sales Submarket: Drivers and Restraints, 2015-2025
Table 6.10 Russian Pharma Contract Sales Submarket: Revenue Forecast ($bn), 2014-2025
Table 7.1 Pharma Contract Sales Market: Strengths and Weaknesses, 2015
Table 7.2 Pharma Contract Sales Market: Opportunities and Threats, 2015-2025
Table 7.3 Selected Blockbuster US Patent Expiries from 2014
Table 7.4 Pharma Contract Sales Market: STEP Analysis, 2015-2025
Table 7.5 Selected CRM Service Providers for Pharma Sales, 2015
Table 7.6 Orphan Drug Definitions in Leading Countries, 2013
Table 7.7 Orphan Drug Pipeline by Disease Area, 2013
Table 8.1 Leading CSOs: Contract Sales and Commercial Service Revenues ($bn), 2013-2014
Table 8.2 Quintiles: Emerging Market Entries: 2010-2012
Table 8.3 Quintiles: Integrated Healthcare Services Revenue ($bn), 2010-2014
Table 8.4 inVentiv Health: Commercial Division Subsidiaries, 2015
Table 8.5 inVentiv Health: Commercial Revenue ($bn), 2010-2014
Table 8.6 UDG Healthcare: Contract Sales Subsidiaries, 2013
Table 8.7 UDG Healthcare: Sales, Marketing and Medical Revenue ($bn), 2010-2014
Table 8.8 PDI: Commercial Services Revenue ($bn), 2010-2014
Table 8.9 Sofip: Revenue ($bn), 2010-2014
Table 8.10 CMIC: CSO Revenue ($bn), 2010-2014
Table 10.1 Pharma Outsourcing Market: Revenues ($bn) and Market Shares (%) by Sector, 2014
Table 10.2 Pharma Contract Sales Market: Revenue Forecasts ($bn) and Market Shares (%) by Service Type 2014, 2019, 2025
Table 10.3 Pharma Contract Sales Market: Revenue Forecasts ($bn) and Market Shares (%) by Therapeutic Area, 2014, 2019 and 2025

List of Figures
Figure 2.1 Services Offered by CSOs in the Pharma Contract Sales Market, 2015
Figure 2.2 Outsourcing Processes in the Pharmaceutical Industry, 2015
Figure 2.3 Trends Driving the Need for New Sales Models, 2015-2025
Figure 3.1 Pharma Contract Sales Market: Revenues ($bn), 2010-2014
Figure 3.2 Pharma Contract Sales Market: Revenue Forecast ($bn), 2015-2025
Figure 3.3 Pharma Contract Sales: Market Drivers, 2015-2025
Figure 3.4 FDA: New Drug Approvals, Numbers, 2010-2014
Figure 3.5 Pharma Contract Sales: Market Restraints, 2015-2025
Figure 3.6 Pharma Contract Sales: Market Shares (%) by Therapeutic Sector, 2014
Figure 3.7 Pharma Contract Sales: Market Shares (%) by Therapeutic Sector, 2019
Figure 3.8 Pharma Contract Sales: Market Shares (%) by Therapeutic Sector, 2025
Figure 3.9 Cardiovascular Disease Submarket: Revenue Forecast ($bn), 2014-2025
Figure 3.10 Metabolic Disorder Submarket: Revenue Forecast ($bn), 2014-2025
Figure 3.11 Oncology Submarket: Revenue Forecast ($bn), 2014-2025
Figure 4.1 Pharma Contract Sales: Market Shares (%) by Service Type, 2014
Figure 4.2 Contract Detailing Submarket: Revenues ($bn), 2010-2014
Figure 4.3 Contract Detailing Submarket: Revenue Forecast ($bn), 2014-2025
Figure 4.4 Contract Detailing Submarket: Drivers and Restraints, 2015-2025
Figure 4.5 Contract Non-Personal Promotion: Submarket Shares (%) by Sector, 2014
Figure 4.6 Contract Non-Personal Promotion Submarket: Revenue Forecast ($bn), 2014-2025
Figure 4.7 Contract Non-Personal Promotion: Submarket Shares (%) by Sector, 2019
Figure 4.8 Contract Non-Personal Promotion: Submarket Shares (%) by Sector, 2025
Figure 4.9 Contract Non-Personal Promotion Submarket: Drivers and Restraints, 2015-2025
Figure 4.10 Contract Teledetailing Submarket: Revenue Forecast ($bn), 2014-2025
Figure 4.11 Contract Teledetailing Submarket: Drivers and Restraints, 2015-2025
Figure 4.12 Contract Edetailing Submarket: Revenue Forecast ($bn), 2014-2025
Figure 4.13 Contract Edetailing Submarket: Drivers and Restraints, 2015-2025
Figure 4.14 Medical Education Services Submarket: Revenue Forecast ($bn), 2014-2025
Figure 4.15 Medical Education Services Submarket: Drivers and Restraints, 2015-2025
Figure 4.16 Sample Management Services Submarket: Revenue Forecast ($bn), 2014-2025
Figure 4.17 Sample Management Services Submarket: Drivers and Restraints, 2015-2025
Figure 4.18 Pharma Contract Sales: Market Shares (%) by Service Type, 2019
Figure 4.19 Pharma Contract Sales: Market Shares (%) by Service Type, 2025
Figure 5.1 Pharma Contract Sales: Market Shares (%) by Region, 2014
Figure 5.2 Pharma Contract Sales: Market Shares (%) by Region, 2019
Figure 5.3 Pharma Contract Sales: Market Shares (%) by Region, 2025
Figure 5.4 US Pharma Contract Sales Submarket: Revenues ($bn), 1995 and 2014
Figure 5.5 US Pharma Contract Sales Submarket: Revenue Forecast ($bn), 2014-2025
Figure 5.6 EU Pharma Contract Sales: Leading National Submarket Shares (%), 2014
Figure 5.7 EU Pharma Contract Sales Submarket: Revenue Forecast ($bn), 2014-2025
Figure 5.8 UK Pharma Contract Sales Submarket: Revenue Forecast ($bn), 2014-2025
Figure 5.9 Growing Rate of Outsourced Sales Reps in Germany, 2003-2013
Figure 5.10 German Pharma Contract Sales Submarket: Revenue Forecast ($bn), 2014-2025
Figure 5.11 French Pharma Contract Sales Submarket: Revenue Forecast ($bn), 2014-2025
Figure 5.12 Italian Pharma Contract Sales Submarket: Revenue Forecast ($bn), 2014-2025
Figure 5.13 Spanish Pharma Contract Sales Submarket: Revenue Forecast ($bn), 2014-2025
Figure 5.14 Japanese Pharma Contract Sales Submarket: Revenue Forecast ($bn), 2014-2025
Figure 6.1 Pharma Contract Sales: Emerging National Market Shares (%), 2019
Figure 6.2 Pharma Contract Sales: Emerging National Market Shares (%), 2025
Figure 6.3 Chinese Pharma Contract Sales Submarket: Revenue Forecast ($bn), 2014-2025
Figure 6.4 Indian Pharma Contract Sales Submarket: Revenue Forecast ($bn), 2014-2025
Figure 6.5 Brazilian Pharma Contract Sales Submarket: Revenue Forecast ($bn), 2014-2025
Figure 6.6 Russian Pharma Contract Sales Submarket: Revenue Forecast ($bn), 2014-2025
Figure 7.1 Orphan Drug Pipeline by Disease Area, 2013
Figure 8.1 Leading CSOs: Contract Sales and Commercial Service Revenues ($bn), 2013-2014
Figure 8.2 Quintiles: Integrated Healthcare Services Revenue ($bn), 2010-2014
Figure 8.3 inVentiv Health: Commercial Revenue ($bn), 2010-2014
Figure 8.4 UDG Healthcare: Sales, Marketing and Medical Revenue ($bn), 2010-2014
Figure 8.5 PDI: Revenue ($bn), 2010-2014
Figure 8.6 Sofip: Revenue ($bn), 2010-2014
Figure 8.7 CMIC: CSO Revenue ($bn), 2010-2014
Figure 10.1 Pharma Outsourcing: Market Shares (%) by Sector, 2014
Figure 10.2 Pharma Contract Sales Market: Revenue Forecasts ($bn) by Service Type, 2014, 2019 and 2025
Figure 10.3 Pharma Contract Sales Market: Revenue Forecast ($bn) by Therapeutic Area, 2014, 2019 and 2025

【掲載企業】

AbbVie
Actavis
Actelion
Agência Nacional de Vigilância Sanitária (ANVISA)
Allergan
Amgen
Apodi
Apple
Arbor Pharms Ireland
Arena Pharmaceuticals
Arista
Ashfield Healthcare
AstraZeneca
Bayer Healthcare
Biogaran
Boehringer Ingelheim
Bristol-Myers Squibb
Catalina Health
Cegedim
Chinese Ministry of Health
Clinical Commissioning Groups (CCGs)
CMIC
Daiichi Sankyo
Dayarn Pharma
Dendreon
Depomed
Eisai
Eli Lilly
Endo Pharmaceuticals
European Federation of Pharmaceutical Industries and Associations (EFPIA)
Expansis
Financial Services Authority (FSA)
Food and Drug Administration (US FDA)
German Federal Court
Gilead
GlaxoSmithKline (GSK)
Go!
Grey Healthcare Group
Health Kare Pharma International
Healthcare Marketing
Helsinn
Hilver
Hospira
In2Focus
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesenis (IQWiG)
International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
inVentive Health
Invida
J. Knipper & Co.
Japan Contract Sales Organization Association (JCSOA)
Johnson&Johnson
Kadrige
L’Agenzia Italiana del Farmaco (AIFA)
Lupin
Mannkind
Marvecs
Medical Communications Group (MCG)
Medical Council of India (MCI)
MediMedia Health
Menarini Asia-Pacific
Merck & Co.
Merqurio Pharma
Microsoft
Ministère des Affaires Sociales et de la Santé
MKM
National Health Service (UK NHS)
National Institute for Health and Care Excellence (UK NICE)
Neurocrine Biosciences
Norwegian Medicines Agency
NovaMed Pharmaceuticals
Novartis
Novo Nordisk
OnCall LLC
Oracle
Otsuka
PDI Healthcare
Pfizer
Pharmaceutical Producers of India (OPPI)
Pharmaceutical Research and Manufacturers of America (PhRMA)
Pharmacyclics
Pharmagistics
Pharmexx
Polpharma
Promius Pharma
Publicis Healthcare Communications Group
Publicis Touchpoint Solutions
Qforma
Quintiles
Ramco Import Export
Roche
Rossetti Marketing
Salesforce
Sanofi
Schering-Plough
Scientific Voice
Sermo
Servier
Sinclair IS Pharma
Smithkline Beecham
Sofip
Solvay
Spectrum Pharmaceuticals
StayInFront
Symplmed Pharmaceuticals
Synopia Rx
Takeda
Temas
Temasek Holdings
Teva Pharmaceutical Industries
Thomas H. Lee Partners
Transgenomic
UDG Healthcare
US Congressional Budget Office
Veeva
Vivus
Warner Chilcott
Zuellig Pharma

【レポートのキーワード】

医薬品販売業務受託機関(CSO)、製薬企業、営業、医薬品、業務代行

★調査レポート[医薬品販売業務受託機関(CSO)の世界市場] ( Pharma Contract Sales Industry and Market: Trends and Forecasts 2015-2025 / VGAIN503176) 販売に関する免責事項
[医薬品販売業務受託機関(CSO)の世界市場] ( Pharma Contract Sales Industry and Market: Trends and Forecasts 2015-2025 / VGAIN503176) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆